Literature DB >> 1506776

Interleukin-6 in mouse hypersensitivity pneumonitis: changes in lung free cells following depletion of endogenous IL-6 or direct administration of IL-6.

M Denis1.   

Abstract

In this study, we examined the role of interleukin-6 (IL-6) in the development of chronic lung inflammatory conditions, using a mouse model of hypersensitivity pneumonitis established by intranasal instillation of the thermophilic actinomycete Faeni rectivirgula. Challenged mice developed an early neutrophilic response at 24 h, followed by a macrophage/lymphocyte recruitment. The impact of IL-6 on the development of the inflammatory response was assessed by giving infusions of a monoclonal antibody against IL-6 so as to deplete endogenous levels of this cytokine or by giving exogenous IL-6 to challenged mice. Mice challenged intranasally with the actinomycete and given the anti-IL-6 antibody developed a strong, sustained neutrophilic response, with a significantly higher lung free cell number than control mice. Assessment of fibrosis by measuring lung hydroxyproline levels showed that challenged mice given anti-IL-6 developed more significant fibrosis than control mice. Conversely, infusions with IL-6 diminished F. rectivirgula-induced cell recruitments and the fibrotic response in the lungs. Moreover, alveolar macrophages from mice given 2 weeks of F. rectivirgula treatment released high levels of tumor necrosis factor alpha (TNF-alpha) bioactivity upon in vitro lipopolysaccharide challenge, compared to mice instilled with saline only. This TNF-alpha activity produced by macrophages was decreased by in vivo IL-6 treatment and enhanced by in vivo neutralization with anti-IL-6. These observations suggest that IL-6 may play a role in regulating the cellular recruitment in the lungs during an inflammatory response, with dramatic consequences for the cellular profile in the bronchoalveolar lavage and the subsequent fibrosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1506776     DOI: 10.1002/jlb.52.2.197

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  16 in total

1.  Antiinflammation and Antioxidant Effects of Thalidomide on Pulmonary Fibrosis in Mice and Human Lung Fibroblasts.

Authors:  Xiaoying Dong; Xin Li; Minghui Li; Ming Chen; Qian Fan; Wei Wei
Journal:  Inflammation       Date:  2017-12       Impact factor: 4.092

2.  OM85-BV induced the productions of IL-1β, IL-6, and TNF-α via TLR4- and TLR2-mediated ERK1/2/NF-κB pathway in RAW264.7 cells.

Authors:  Hong Luan; Qian Zhang; Le Wang; Chuanxiao Wang; Miao Zhang; Xiaoli Xu; Huan Zhou; Xing'ai Li; Qing Xu; Fan He; Jin Yuan; Yongman Lv
Journal:  J Interferon Cytokine Res       Date:  2014-03-07       Impact factor: 2.607

3.  Regulatory effects of interleukin-6 in immunoglobulin G immune-complex-induced lung injury.

Authors:  T P Shanley; J L Foreback; D G Remick; T R Ulich; S L Kunkel; P A Ward
Journal:  Am J Pathol       Date:  1997-07       Impact factor: 4.307

4.  Induction of interleukin 6 and interleukin 8 expression by Broncho-Vaxom (OM-85 BV) via C-Fos/serum responsive element.

Authors:  R Keul; M Roth; E Papakonstantinou; M Nauck; A P Perruchoud; L H Block
Journal:  Thorax       Date:  1996-02       Impact factor: 9.139

5.  Distinct effects of Broncho-Vaxom (OM-85 BV) on gp130 binding cytokines.

Authors:  M Roth; L H Block
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

6.  A regulatory role for interleukin 4 in differential inflammatory responses in the lung following infection of mice primed with Th1- or Th2-inducing pertussis vaccines.

Authors:  P McGuirk; K H Mills
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

7.  Airway epithelial cell expression of interleukin-6 in transgenic mice. Uncoupling of airway inflammation and bronchial hyperreactivity.

Authors:  B F DiCosmo; G P Geba; D Picarella; J A Elias; J A Rankin; B R Stripp; J A Whitsett; R A Flavell
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

8.  Inhibitory Effects of Astragaloside IV on Bleomycin-Induced Pulmonary Fibrosis in Rats Via Attenuation of Oxidative Stress and Inflammation.

Authors:  Wei-Na Yu; Li-Feng Sun; Hua Yang
Journal:  Inflammation       Date:  2016-10       Impact factor: 4.092

9.  Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice.

Authors:  Sergey Udalov; Rio Dumitrascu; Soni S Pullamsetti; Hamza M Al-tamari; Norbert Weissmann; Hossein A Ghofrani; Andreas Guenther; Robert Voswinckel; Werner Seeger; Friedrich Grimminger; Ralph T Schermuly
Journal:  BMC Pulm Med       Date:  2010-05-05       Impact factor: 3.317

10.  Inhibitory effects of thalidomide on bleomycin-induced pulmonary fibrosis in rats via regulation of thioredoxin reductase and inflammations.

Authors:  Xiaoying Dong; Xin Li; Minghui Li; Ming Chen; Qian Fan; Wei Wei
Journal:  Am J Transl Res       Date:  2017-10-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.